Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis-Reference-Cited by-同舟云学术

Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis

Published:2019-03-11 Issue:1 Volume:181 Page:202-203
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Romiti R.¹,Valenzuela F.²,Chouela E.N.³,Xu W.⁴,Pangallo B.⁴,Moriarty S.R.⁴,Gürbüz S.⁴,Riedl E.⁵⁶

Affiliation:

1. Universidade de São Paulo São Paulo Brazil

2. University of Chile and Probity Medical Research Santiago Chile

3. Hospital General de Agudos Buenos Aires Argentina

4. Eli Lilly and Company, Indianapolis IN U.S.A

5. Medical University of Vienna ViennaAustria

6. Eli Lilly Regional Operations GmbH Vienna Austria

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.17604

Reference8 articles.

1. World Health Organization.Global tuberculosis report 2018. Available at:http://www.who.int/tb/publications/global_report/en/(last accessed 10 December 2018).

2. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling

3. Psoriasis: Which therapy for which patient

4. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections

5. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent;J BRAS PNEUMOL;2024

2. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure;Annals of the Rheumatic Diseases;2022-04-07

3. Practical management of patients on anti-IL17 therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI);Joint Bone Spine;2021-05

4. Ixekizumab in the treatment of psoriatic arthritis;Immunotherapy;2021-01

5. Safety of secukinumab in psoriasis patients with latent tuberculosis infection;European Journal of Dermatology;2020-12